IL6

Second Front Systems Enables Deployment of Learn to Win to DoD Impact Level 6

Retrieved on: 
Friday, April 26, 2024
Entrepreneurship, Software, 2F, IL6, Organization

WILMINGTON, Del., April 26, 2024 /PRNewswire/ -- Second Front Systems (2F), a public-benefit software company focused on facilitating the delivery of mission-critical software solutions, today announced the availability of Learn to Win, a leading commercial provider of training software, to DoD Impact Level 6 (IL6) through 2F's Game Warden.

Key Points: 
  • By providing commercial leading learning software at this Impact Level, Learn to Win is able to provide customized and personalized learning to organizations working on classified use cases and mission sets.
  • Learn to Win is the first application to reach IL6 through Game Warden, a significant achievement for both organizations.
  • Leveraging Game Warden has helped us achieve that goal for our 20+ DoD customer organizations," said Andrew Powell, Learn to Win's Co-Founder and CEO.
  • "This software deployment at IL6 solidifies and furthers our stance as a trusted technology partner to the DoD at the most secure level."

Oracle Cloud Secret Impact Level 6 Regions for U.S. Department of Defense

Retrieved on: 
Monday, April 22, 2024
Cloud, HPC, Information, Cloud computing, News, Woman, AI, Defense Information Systems Agency, Communication, DISA, Environment, Accreditation, Classification, IL6, Secrecy, Oracle Cloud, Information technology

AUSTIN, Texas, April 22, 2024 /PRNewswire/ -- Oracle today announced the accreditation of three cloud regions for the U.S. Department of Defense (DoD) with Defense Information Systems Agency (DISA) Impact Level 6 (IL6) authorization to host Secret classified workloads. Oracle Cloud Infrastructure is now available at all DoD classification levels, providing defense customers support for their full technology portfolio and more capability to fulfill their mission.

Key Points: 
  • AUSTIN, Texas, April 22, 2024 /PRNewswire/ -- Oracle today announced the accreditation of three cloud regions for the U.S. Department of Defense (DoD) with Defense Information Systems Agency (DISA) Impact Level 6 (IL6) authorization to host Secret classified workloads.
  • Oracle Cloud Infrastructure is now available at all DoD classification levels, providing defense customers support for their full technology portfolio and more capability to fulfill their mission.
  • Oracle Cloud classified regions come with our Everything Everywhere® commitment to offer the same Oracle Cloud services that are available in the Oracle public cloud.
  • Oracle Cloud classified regions are supported and managed from secure, dedicated, cloud network operation centers, which are only accessed, monitored, and staffed by U.S. government-cleared personnel.

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

Sigma Defense Systems Launches Sigma Software Studio - A New DevSecOps Platform

Retrieved on: 
Monday, February 12, 2024
Accreditation, IL6, DIY, Government, Authority, Organization, Navy, USMC, Software, Video game

PERRY, Ga., Feb. 12, 2024 /PRNewswire/ -- Sigma Defense Systems is proud to announce the launch of Sigma Software Studio, a cutting-edge DevSecOps platform poised to revolutionize software development for the DoD and government agencies.

Key Points: 
  • PERRY, Ga., Feb. 12, 2024 /PRNewswire/ -- Sigma Defense Systems is proud to announce the launch of Sigma Software Studio, a cutting-edge DevSecOps platform poised to revolutionize software development for the DoD and government agencies.
  • Sigma Defense Systems announces the launch of Sigma Software Studio, a DevSecOps platform for government and DoD.
  • Rooted in Sigma's collaboration with PEO Digital and Black Pearl, Sigma Software Studio, is a DevSecOps platform designed for transformation and software modernization across the Department of the Navy.
  • By providing a proven, secure DevSecOps platform that unifies and streamlines software development processes, Sigma Software Studio, accelerates the deployment of software applications and significantly lowers costs compared to traditional DIY approaches.

Summit 7 Invests in The Future of Classified IT Managed Services and Compliance with Acquisition of CSW Systems

Retrieved on: 
Wednesday, November 1, 2023
Department of Defense Cyber Crime Center, Intelligence community, United States Department of Defense, IL4, Impact, Acquisition, Summit, CSW, IL6, IC, Defense industrial base, Ecosystem, Partnership, Intelligence

HUNTSVILLE, Ala., Nov. 1, 2023 /PRNewswire/ -- Summit 7, the leading provider of cybersecurity and compliance services for the Defense Industrial Base, is proud to announce the acquisition of CSW Systems, the leading provider of managed services and continuous compliance support for classified data processing facilities.

Key Points: 
  • HUNTSVILLE, Ala., Nov. 1, 2023 /PRNewswire/ -- Summit 7, the leading provider of cybersecurity and compliance services for the Defense Industrial Base, is proud to announce the acquisition of CSW Systems, the leading provider of managed services and continuous compliance support for classified data processing facilities.
  • This acquisition will further enable Summit 7 to provide services regarding Classified initiatives in the Department of Defense (DoD) and Intelligence Community (IC) supply chains.
  • This strategic acquisition further solidifies Summit 7's position as a comprehensive provider of cutting-edge solutions for the DoD, IC, and its affiliated contractors.
  • "We are thrilled to welcome the talented team at CSW Systems into the Summit 7 team," said Scott Edwards, CEO at Summit 7.

Aalyria and Second Front Partner to Expedite Availability of Spacetime for Government Use

Retrieved on: 
Wednesday, October 11, 2023
Defense, Technology, Software, Government Technology, Networks, Other Defense, Contracts, IL4, Partnership, Spacetime, Intelligence, Private sector, Second Front: Germany Turns East, Conservation officer, Ilyushin Il-4, Western Front (World War II), Aircraft, Ship, Defense Innovation Unit, IL5, Intelsat, Second, SOCOM U.S. Navy SEALs: Confrontation, ILS, IL6, Atmosphere, Management, Cryptocurrency

Aalyria , a dynamic startup commercializing advanced networking and communications technologies acquired from Google , has formed a strategic alliance with Second Front Systems.

Key Points: 
  • Aalyria , a dynamic startup commercializing advanced networking and communications technologies acquired from Google , has formed a strategic alliance with Second Front Systems.
  • This collaboration paves the way for accelerated deployment of Aalyria’s Spacetime network orchestration platform within government sectors.
  • The integration with Second Front's trusted Game Warden platform makes Spacetime accessible at Department of Defense Impact Levels 4 and 5 (IL4 and IL5).
  • Aalyria and Second Front will focus on Aalryia’s TRL 9 Spacetime offering – a product validated with greater than 2 million hours of lights-out orchestration of aerospace nodes.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Retrieved on: 
Monday, July 17, 2023
Cognition, Inflammation, COPD, DNA, Precuneus, Methylation, Tau, Guanine, In vivo magnetic resonance spectroscopy, Public key certificate, Neuroimaging, Deficit spending, IL10, Brain, Gene expression, Biomarker, MCI, IL6, Plasma, CDR, Cytosine, AAIC, Oxidative stress, MRS, Volume, Patient, DSM-IV codes, LRRFIP1, CSF, Glutathione, DNaM, Probability, Poster, ADAS, DNA methylation, AD, Diagnosis, Gene, Conference, Antioxidant, Hippocampus, Disease, Medical imaging, Pharmaceutical industry

Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various biomarkers.

Key Points: 
  • Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various biomarkers.
  • Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.
  • The poster was presented yesterday at the Alzheimer’s Associate’s International Conference (AAIC) held in Amsterdam July 16-20, 2023.
  • The new data that was presented details how NE3107 may potentially change or affect the degree of methylation of specific genes that are correlated with various markers of disease.

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Gastrointestinal cancer, PRAME, Patient, Ipilimumab, Commercial, IMC, Uveal melanoma, Infection, Research, MAD, Conference, Book, Safety, Abstract, DNA, AACR, HLA, Cancer, Record, BRAF, Medicine, Immunotherapy, TCR, CROI, James A. Schlipmann Melanoma Cancer Foundation, PIWIL1, Neoplasm, ImmTAC, Arm, HIV, OS, CTA, Fungal infection, Mum, Sale, ASCO, CTAS, American Society of Clinical Oncology, Melanoma, Annual general meeting, IND Queens Boulevard Line, Viral load, Society, Pharmaceutical industry, Cryptocurrency, Communications satellite, Immunocore, IL6

During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.

Key Points: 
  • During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
  • In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK.
  • The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND / CTA in the fourth quarter of 2023.

NextGen Sensors Set to Enable Real-Time IBD Disease Management after Funding Boost

Retrieved on: 
Wednesday, April 12, 2023
Health Technology, Other Consumer, Biotechnology, Finance, Women, Seniors, Other Science, Health, Research, Professional Services, Men, Consumer, Other Technology, Nanotechnology, Wearables, Mobile Technology, Science, Other Health, Hardware, Data Management, Managed Care, Telemedicine, Virtual Medicine, General Health, Technology, Biometrics, Medical Devices, Translation, University, Icahn School of Medicine at Mount Sinai, IBD, AWARE, Quality of life, Cortisol, Mount Sinai, Interleukin 6, Inflammation, Biomarker, IL6, Inflammatory bowel disease, Organization, Patient, Investment, CRP, Risk, Recurrence, Perspiration, Skin, Disease, C-reactive protein, Financial adviser, Medical imaging, Pharmaceutical industry, Calprotectin

IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).

Key Points: 
  • IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).
  • Additional details about the IBD AWARE platform and how it works can be found at https://www.ibdwearable.com .
  • “IBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further quality of life outcomes.
  • The Crohn’s & Colitis Foundation launched IBD Ventures to accelerate the discovery and development of research-based products with the potential to address unmet needs of IBD patients.